Research News on Targeted Therapies
-
Adding Tykerb to Herceptin and Chemo Improves Survival in Metastatic, HER2-Positive Disease
Research suggests that treating women diagnosed with metastatic, HER2-positive breast cancer with Tykerb and Herceptin and chemotherapy improves survival compared to only Herceptin and chemotherapy.
-
Experimental Dovitinib Seems to Offer No Benefits for Metastatic, HER2-Negative Disease
A very small, very early study found that the experimental targeted therapy dovitinib didn't benefit women diagnosed with metastatic, HER2-negative breast cancer.
-
Tykerb and Xeloda Can Help Treat Breast Cancer That’s Spread to the Brain
A small, early study found that treating women diagnosed with metastatic, HER2-positive breast cancer that has spread to the brain with a combination of Tykerb and Xeloda can shrink the cancer in some women.
-
Nexavar May Help Treat Some Metastatic Breast Cancers
Research suggests that some women diagnosed with advanced-stage breast cancer benefit more from chemotherapy and Nexavar compared to chemotherapy and placebo (a sugar pill).
-
New Medicines That Slow Cancer’s Growth Don’t Seem to Improve Survival
Research shows no link between progression-free survival and overall survival in experimental breast cancer treatment trials.
-
Avastin Slows Growth of Metastatic Breast Cancer
Women diagnosed with metastatic breast cancer who got Avastin in combination with chemotherapy lived 1 to 3 months longer without the cancer growing compared to women who only got chemotherapy, but overall survival was the same for both groups.
-
Herceptin After Surgery Reduces Recurrence Risk of HER2-Positive, Early-Stage Disease
New research shows women diagnosed with early-stage, HER2-positive breast cancer who were treated with adjuvant chemotherapy then Herceptin for 1 year were 24% less likely to have the cancer come back compared to women who got adjuvant chemotherapy but no Herceptin.
-
Avastin Not Recommended to Treat Breast Cancer by British Agency
Echoing the FDA decision, the British National Institute for Health and Clinical Excellence hasn't approved using Avastin to treat metastatic breast cancer.
-
Experimental Iniparib Increases Survival Only Slightly in Metastatic Triple-Negative Disease
A large study found that iniparib didn't improve survival in women diagnosed with metastatic triple-negative breast cancer, which contradicts results from earlier studies.
-
Genentech Asks FDA for Full Hearing on Avastin
Genentech, the company that makes Avastin, has asked for a full FDA hearing to again present currently available research on Avastin and to review plans for future research.
